Adaptive Biotechnologies Corporation $ADPT Shares Sold by Knights of Columbus Asset Advisors LLC

Knights of Columbus Asset Advisors LLC trimmed its position in shares of Adaptive Biotechnologies Corporation (NASDAQ:ADPT – Free Report) by 34.5% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 100,441 shares of the company’s stock after selling 52,845 shares during the period. Knights of Columbus Asset Advisors LLC owned 0.06% of Adaptive Biotechnologies worth $2,903,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. BlackRock Inc. acquired a new stake in shares of Adaptive Biotechnologies in the second quarter valued at approximately $324,735,000. Wellington Management Group LLP raised its holdings in shares of Adaptive Biotechnologies by 53.2% during the second quarter. Wellington Management Group LLP now owns 5,911,366 shares of the company’s stock valued at $126,799,000 after buying an additional 2,053,944 shares during the last quarter. Bank of America Corp DE bought a new stake in shares of Adaptive Biotechnologies during the second quarter valued at approximately $37,109,000. Freestone Grove Partners LP acquired a new position in shares of Adaptive Biotechnologies during the second quarter worth approximately $18,912,000. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of Adaptive Biotechnologies during the second quarter worth approximately $16,858,000. Institutional investors own 99.17% of the company’s stock.

Adaptive Biotechnologies Stock Performance

Adaptive Biotechnologies stock opened at $29.94 on Thursday. Adaptive Biotechnologies Corporation has a 52 week low of $12.00 and a 52 week high of $32.21. The company’s 50-day moving average price is $26.72 and its two-hundred day moving average price is $20.03. The company has a debt-to-equity ratio of 1.82, a current ratio of 3.97 and a quick ratio of 3.87.

Adaptive Biotechnologies (NASDAQ:ADPT – Get Free Report) last issued its quarterly earnings results on Wednesday, November 4th. The company reported $0.02 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.12. The company had revenue of $83.90 million during the quarter, compared to analyst estimates of $71.57 million. Adaptive Biotechnologies had a negative net margin of 23.67% and a negative return on equity of 23.95%. The business’s revenue for the quarter was down 10.7% compared to the same quarter last year. During the same period in the prior year, the business posted $0.06 EPS. As a group, analysts expect that Adaptive Biotechnologies Corporation will post -0.29 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently issued reports on ADPT. Morgan Stanley increased their price objective on Adaptive Biotechnologies from $22.00 to $27.00 and gave the stock an “equal weight” rating in a report on Monday, October 12th. The Goldman Sachs Group initiated coverage on Adaptive Biotechnologies in a research note on Tuesday, September 29th. They set a “buy” rating and a $35.00 target price on the stock. National Bank Financial set a $34.00 price target on Adaptive Biotechnologies in a research report on Tuesday, September 22nd. BTIG Research boosted their price target on Adaptive Biotechnologies from $25.00 to $34.00 and gave the stock a “buy” rating in a research report on Tuesday, September 22nd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research note on Thursday, October 15th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $30.31.

Check Out Our Latest Analysis on Adaptive Biotechnologies

Insider Buying and Selling

In related news, COO Julie Rubinstein sold 11,881 shares of the business’s stock in a transaction that occurred on Monday, November 9th. The stock was sold at an average price of $30.12, for a total transaction of $357,855.72. Following the sale, the chief operating officer owned 377,802 shares of the company’s stock, valued at $11,379,396.24. The trade was a 3.05% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 1,071,525 shares of company stock worth $27,404,692 over the last quarter. 5.70% of the stock is owned by insiders.

Adaptive Biotechnologies Profile

(Free Report)

Adaptive Biotechnologies is a biotechnology company focused on using the human immune system to diagnose and treat disease. Based in Seattle, Washington, the company develops technologies that sequence and analyze immune cells and their receptors, generating data for clinical testing, research and drug development. Its products include immunoSEQ, a platform used by researchers and biopharmaceutical companies to study immune responses, and clonoSEQ, a clinical test that detects and monitors minimal residual disease in certain blood cancers.

Featured Articles

Want to see what other hedge funds are holding ADPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Adaptive Biotechnologies Corporation (NASDAQ:ADPT – Free Report).

Institutional Ownership by Quarter for Adaptive Biotechnologies (NASDAQ:ADPT)

Receive News & Ratings for Adaptive Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptive Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.